LARS2
Basic information
Region (hg38): 3:45388561-45554726
Links
Phenotypes
GenCC
Source:
- Perrault syndrome 4 (Strong), mode of inheritance: AR
- hydrops-lactic acidosis-sideroblastic anemia-multisystemic failure syndrome (Limited), mode of inheritance: AR
- Perrault syndrome (Supportive), mode of inheritance: AR
- hydrops-lactic acidosis-sideroblastic anemia-multisystemic failure syndrome (Strong), mode of inheritance: AR
- Perrault syndrome 4 (Strong), mode of inheritance: AR
- Perrault syndrome (Strong), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Perrault syndrome 4 | AR | Audiologic/Otolaryngologic; Biochemical; Endocrine; Gastrointestinal; Hematologic; Neurologic; Obstetric | Genetic knowledge may allow fertility preservation such as by storing eggs in woman with premature ovarian failure | Audiologic/Otolaryngologic; Endocrine; Genitourinary; Hematologic; Obstetric; Pulmonary | 23541342; 26537577; 32442335 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (13 variants)
- Perrault syndrome 4 (4 variants)
- Nonsyndromic genetic hearing loss (2 variants)
- Perrault syndrome (2 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the LARS2 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 99 | 10 | 110 | |||
missense | 13 | 145 | 171 | |||
nonsense | 13 | |||||
start loss | 0 | |||||
frameshift | 9 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 4 | |||||
splice region | 4 | 19 | 1 | 24 | ||
non coding | 87 | 44 | 132 | |||
Total | 17 | 24 | 148 | 193 | 57 |
Highest pathogenic variant AF is 0.0000460
Variants in LARS2
This is a list of pathogenic ClinVar variants found in the LARS2 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
3-45388659-G-A | Benign (Jun 29, 2018) | |||
3-45388665-C-G | not specified | Likely benign (May 15, 2017) | ||
3-45388686-C-A | not specified | Likely benign (Nov 03, 2017) | ||
3-45388690-C-G | not specified | Likely benign (Apr 07, 2017) | ||
3-45388753-C-G | Benign (Jun 29, 2018) | |||
3-45391483-C-A | Likely benign (Aug 28, 2020) | |||
3-45391634-G-A | not specified | Benign (Feb 02, 2016) | ||
3-45391775-C-G | Likely benign (Jun 29, 2018) | |||
3-45394190-T-C | Likely benign (Jul 15, 2018) | |||
3-45394357-A-T | Benign (Jun 26, 2018) | |||
3-45394420-C-T | not specified | Likely benign (Jan 24, 2018) | ||
3-45394475-T-C | not specified • LARS2-related disorder | Benign (Jan 22, 2024) | ||
3-45394493-CTT-C | Perrault syndrome 4 | Pathogenic (-) | ||
3-45394512-A-G | Uncertain significance (Sep 06, 2023) | |||
3-45394542-G-A | Uncertain significance (Feb 01, 2022) | |||
3-45394551-T-C | Uncertain significance (Jun 08, 2022) | |||
3-45394555-C-T | Likely benign (May 27, 2023) | |||
3-45394556-G-A | Uncertain significance (Jul 12, 2022) | |||
3-45394566-GA-G | Pathogenic (Jan 01, 2024) | |||
3-45394578-G-A | Uncertain significance (Dec 15, 2020) | |||
3-45394588-A-T | Uncertain significance (Sep 28, 2022) | |||
3-45394596-CAA-C | Pathogenic (Sep 30, 2022) | |||
3-45394598-A-G | Uncertain significance (Jan 19, 2024) | |||
3-45394601-G-A | Inborn genetic diseases | Uncertain significance (Mar 13, 2023) | ||
3-45394610-T-C | not specified | Benign (Jan 31, 2024) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
LARS2 | protein_coding | protein_coding | ENST00000415258 | 20 | 160916 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
8.93e-17 | 0.952 | 125645 | 0 | 103 | 125748 | 0.000410 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.33 | 427 | 512 | 0.834 | 0.0000275 | 5914 |
Missense in Polyphen | 135 | 209.55 | 0.64424 | 2460 | ||
Synonymous | 0.485 | 185 | 194 | 0.956 | 0.0000110 | 1729 |
Loss of Function | 2.40 | 34 | 52.8 | 0.644 | 0.00000255 | 587 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000653 | 0.000652 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00104 | 0.00103 |
Finnish | 0.000139 | 0.000139 |
European (Non-Finnish) | 0.000406 | 0.000396 |
Middle Eastern | 0.00104 | 0.00103 |
South Asian | 0.000633 | 0.000621 |
Other | 0.000326 | 0.000326 |
dbNSFP
Source:
- Disease
- DISEASE: Hydrops, lactic acidosis, and sideroblastic anemia (HLASA) [MIM:617021]: A lethal, multisystem metabolic disorder characterized by severe lactic acidosis, hydrops, and sideroblastic anemia. Additional features include impaired cardiac function, disordered coagulation, pulmonary hypertension, and progressive renal disease. {ECO:0000269|PubMed:26537577}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Aminoacyl-tRNA biosynthesis - Homo sapiens (human);Amino Acid metabolism;tRNA Aminoacylation;Translation;Metabolism of proteins;tRNA charging;Valine, leucine and isoleucine degradation;Mitochondrial tRNA aminoacylation
(Consensus)
Recessive Scores
- pRec
- 0.233
Intolerance Scores
- loftool
- 0.567
- rvis_EVS
- -0.75
- rvis_percentile_EVS
- 13.74
Haploinsufficiency Scores
- pHI
- 0.526
- hipred
- N
- hipred_score
- 0.414
- ghis
- 0.584
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- E
- essential_gene_gene_trap
- E
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.997
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Lars2
- Phenotype
Gene ontology
- Biological process
- tRNA aminoacylation for protein translation;leucyl-tRNA aminoacylation;mitochondrial translation;aminoacyl-tRNA metabolism involved in translational fidelity
- Cellular component
- mitochondrion;mitochondrial matrix
- Molecular function
- aminoacyl-tRNA editing activity;leucine-tRNA ligase activity;ATP binding